Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)
Induction Therapy With Gefitinib Followed by Taxane Platinum Chemotherapy and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial.
Sponsor: AIO-Studien-gGmbH
Terminated
Due to low patient enrollment was stopped. Only one patient could be enrolled. 37 patients were pre-screened, but not into the inclusion criteria (wt-EGFR)
Other terminated trials from AIO-Studien-gGmbH
A PHASE2/PHASE3 clinical study on Activating EGFR Mutation and NSCLC, this trial is terminated or withdrawn. The trial is conducted by AIO-Studien-gGmbH and has accumulated 10 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2_PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2_PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Feb 2018 — May 2018 [monthly]
Terminated PHASE2_PHASE3
-
Sep 2017 — Feb 2018 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AIO-Studien-gGmbH
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .